Immuno-Oncology 360° is a comprehensive program providing exposure to the entire spectrum of R&D, addressing key aspects from all facets of IO including:
AstraZeneca is planning filings of its chronic obstructive pulmonary disease drug Bevespi Aerosphere in China and Japan, based on a new set of positive phase 3 trial results.
